Skip to content
OpenCapital
Get started

Icahn Enterprises IEP Pharma — D&A

Other segment segments

Energy
$96M+14.3%
Automotive
$12M-29.4%
Food Packaging
$4M-20.0%
Home Fashion
$1M0.0%

Other financials

Income statement

See full
Revenue$2.2B+18.2%
Net income-$459.0M-8.8%
EPS (diluted)-$0.71+10.1%

Balance sheet

See full
Cash & equivalents$1.3B-40.5%
Total debt$6.9B-5.9%
Total assets$12.9B-16.5%

Cash flow

See full
Operating cash flow$397.0M+318%
CapEx$114.0M+29.5%
Free cash flow$283.0M+205%

Valuation

See full
Market cap$4.9B+1.6%

Profitability

See full
Gross margin-56.5%—
Net margin-3.4%-1.3pp
FCF margin20%—

Returns & leverage

See full
Return on equity-0.1%—
Debt / equity0.7×—

Where this comes from

Reported directly by Icahn Enterprises in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: Icahn Enterprises’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Icahn Enterprises's pharma — d&a.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Icahn Enterprises's pharma — D&A?
Icahn Enterprises (IEP) reported pharma — D&A of $2M in Q1 2026.
How has Icahn Enterprises's pharma — D&A changed year-over-year?
Icahn Enterprises's pharma — D&A decreased by 71.4% year-over-year, from $7M to $2M.
What is the long-term trend for Icahn Enterprises's pharma — D&A?
Over 4 years (2021 to 2025), Icahn Enterprises's pharma — D&A has grown at a 0.0% compound annual growth rate (CAGR), from $28M to $28M.
What does pharma — D&A mean?
Represents the non-cash allocation of costs for tangible and intangible assets over their useful lives within the Pharma segment. This metric highlights the capital intensity of the business and the ongoing investment required to maintain operational capacity. It is a critical component for calculating cash flow metrics and understanding asset utilization.